Physician profile
Joel Pleeter
NPI 1013050467
$3,359.10
in general payments reported to CMS, 2019-2025
31 companies · $671 in 2025
The $671 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $336 · 2021: $538 · 2022: $417 · 2023: $590 · 2024: $482 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,529 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,528.65 |
| Education | $213.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $553.62 | 2023-2025 | Veozah |
| Abbvie INC. | $528.55 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $328.13 | 2021-2025 | |
| Sage Therapeutics, LLC | $280.70 | 2020-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $230.39 | 2019-2022 | |
| Hologic Sales and Service, LLC | $196.21 | 2021-2025 | Coolseal Generator, Aptima, Fluent Fluid Management System |
| Pfizer INC. | $156.23 | 2019-2025 | |
| Caldera Medical, INC | $138.69 | 2025 | |
| Evofem Biosciences, INC. | $115.78 | 2022-2025 | Solosec, Phexx, Phexxi |
| Coopersurgical, INC. | $103.35 | 2019-2023 | Paragard T 380a, Summit Doppler |
| Amgen INC. | $85.92 | 2020-2025 | Prolia, Evenity |
| Amag Pharmaceuticals, INC. | $72.28 | 2019-2020 | |
| Organon LLC | $67.71 | 2021-2022 | |
| Millicent US INC | $67.17 | 2023-2024 | Femring, Intrarosa |
| Allergan, INC. | $43.24 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $39.90 | 2023-2024 | Myfembree |
| Merck Sharp & Dohme LLC | $36.52 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.83 | 2024 | Vpriv |
| Baxter Healthcare | $32.31 | 2025 | Seprafilm |
| Avion Pharmaceuticals | $28.33 | 2021-2022 | |
| Myriad Women'S Health, INC. | $26.43 | 2023 | Myrisk |
| Mylan Pharmaceuticals INC. | $23.88 | 2021 | |
| Daiichi Sankyo INC. | $23.53 | 2019 | |
| Duchesnay USA Incorporated | $22.94 | 2019 | |
| Supernus Pharmaceuticals, INC. | $22.36 | 2025 | Qelbree |
| Agile Therapeutics, INC. | $22.22 | 2022 | |
| Becton, Dickinson and Company | $21.31 | 2019 | |
| Exeltis, USA INC. | $18.42 | 2024 | Slynd |
| Myovant Sciences INC. | $15.90 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.64 | 2020 | |
| Roche Diagnostics Corporation | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Pleeter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.